CUAMC
China Universal Asset Management Company Portfolio holdings
AUM
$1.06B
1-Year Return
31.81%
This Quarter Return
+22.53%
1 Year Return
+31.81%
3 Year Return
+205.04%
5 Year Return
–
10 Year Return
–
AUM
$295M
AUM Growth
+$46.7M
(+19%)
Cap. Flow
+$10.2M
Cap. Flow
% of AUM
3.44%
Top 10 Holdings %
Top 10 Hldgs %
32.39%
Holding
456
New
65
Increased
317
Reduced
38
Closed
9
Top Buys
| 1 |
NVIDIA
NVDA
|
$7.81M |
| 2 |
PayPal
PYPL
|
$4.77M |
| 3 |
STAAR Surgical
STAA
|
$3.64M |
| 4 |
Chipotle Mexican Grill
CMG
|
$3.46M |
| 5 |
Microsoft
MSFT
|
$3.33M |
Top Sells
| 1 |
iQIYI
IQ
|
$7.64M |
| 2 |
Pinduoduo
PDD
|
$6.59M |
| 3 |
ON Semiconductor
ON
|
$4.45M |
| 4 |
Apple
AAPL
|
$3.07M |
| 5 |
Rambus
RMBS
|
$2.77M |
Sector Composition
| 1 | Technology | 38.43% |
| 2 | Consumer Discretionary | 23.55% |
| 3 | Healthcare | 18.31% |
| 4 | Communication Services | 8.83% |
| 5 | Financials | 4.58% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
226
Iovance Biotherapeutics
IOVA
$905M
| $18.6K | 0.01% |
3,038
+1,435
| +90% | +$8.77K |
|
|
DICE
227
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
| $18.5K | 0.01% |
646
+162
| +33% | +$4.64K |
|
228
Rocket Pharmaceuticals
RCKT
$353M
| $18.4K | 0.01% |
1,075
+306
| +40% | +$5.24K |
|
229
Arcellx
ACLX
$4.03B
| $18.3K | 0.01% |
594
+149
| +33% | +$4.59K |
|
230
Nuvalent
NUVL
$5.83B
| $18K | 0.01% |
691
+173
| +33% | +$4.51K |
|
231
Charles River Laboratories
CRL
$8.07B
| $18K | 0.01% |
89
| – | – |
|
232
Cadence Design Systems
CDNS
$95.6B
| $17.4K | 0.01% |
+83
| New | +$17.4K |
|
|
VRNA
233
Verona Pharma
VRNA
$9.2B
| $17.3K | 0.01% |
862
+245
| +40% | +$4.92K |
|
234
Agios Pharmaceuticals
AGIO
$2.09B
| $17.2K | 0.01% |
749
+191
| +34% | +$4.39K |
|
235
Adaptive Biotechnologies
ADPT
$1.96B
| $17.1K | 0.01% |
1,940
+487
| +34% | +$4.3K |
|
236
Monster Beverage
MNST
$61B
| $17.1K | 0.01% |
+316
| New | +$17.1K |
|
237
Ligand Pharmaceuticals
LGND
$3.25B
| $17K | 0.01% |
231
+60
| +35% | +$4.41K |
|
238
KLA
KLAC
$120B
| $16.8K | 0.01% |
+42
| New | +$16.8K |
|
239
IQVIA
IQV
$31.9B
| $16.7K | 0.01% |
84
| – | – |
|
240
Recursion Pharmaceuticals
RXRX
$2.02B
| $16.6K | 0.01% |
2,485
+639
| +35% | +$4.26K |
|
241
Summit Therapeutics
SMMT
$19.3B
| $16.5K | 0.01% |
9,453
+7,408
| +362% | +$13K |
|
242
Charter Communications
CHTR
$35.7B
| $16.5K | 0.01% |
+46
| New | +$16.5K |
|
243
O'Reilly Automotive
ORLY
$89B
| $16.1K | 0.01% |
+285
| New | +$16.1K |
|
244
Keros Therapeutics
KROS
$632M
| $15.9K | 0.01% |
373
+93
| +33% | +$3.97K |
|
|
DCPH
245
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $15.9K | 0.01% |
1,029
+342
| +50% | +$5.28K |
|
246
Marriott International Class A Common Stock
MAR
$71.9B
| $15.4K | 0.01% |
+93
| New | +$15.4K |
|
247
Protagonist Therapeutics
PTGX
$3.77B
| $15.3K | 0.01% |
667
+167
| +33% | +$3.84K |
|
248
Keurig Dr Pepper
KDP
$38.9B
| $15K | 0.01% |
+425
| New | +$15K |
|
249
JD.com
JD
$44.6B
| $14.9K | 0.01% |
339
+139
| +70% | +$6.1K |
|
250
Avidity Biosciences
RNA
$6.48B
| $14.7K | 0.01% |
959
+406
| +73% | +$6.23K |
|